<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56458">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371148</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_BRB</org_study_id>
    <nct_id>NCT02371148</nct_id>
  </id_info>
  <brief_title>Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's</brief_title>
  <acronym>FIL_BRB</acronym>
  <official_title>Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory
      Waldenstrom's Macroglobulinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The progression free survival (PFS) expected for lymphoplasmacytic/lymphoplasmocytoid
      lymphoma/Waldenstrom macroglobulinemia with the same characteristics indicated into the
      study and treated with standard Rituximab plus chemotherapy may be estimated to be 50% at 18
      months.

      The Investigators would consider a positive result to increase 18 months-PFS rate from 50 to
      65%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>This is a prospective, multicenter phase II trial designed to determine efficacy and safety of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory Waldenstrom's Macroglobulinemia. Primary Objective is to assess whether the experimental treatment achieves an absolute increase of PFS rate from 50 to 65% at 18 months with respect to the standard treatment. PFS is measured from the beginning of therapy to the date of disease progression, relapse or death from any cause.
Patients without any relapse at the end of the follow-up will be censored at their last assessment date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall response rate (ORR): a patient is defined as a responder if he has a complete or very good partial or partial response, evaluated in based on Waldenstrom macroglobulinemia consensus recommendations of the 6th International Workshop on Waldestrom's macroglobulinemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS): measured from the beginning of therapy to the date of death from any cause. Patients alive at the time of the final analysis will be censored at the date of the last contact. Minimum follow up time required for all patients will be 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity: severe, life- threatening, fatal (grade 3, 4 and 5)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events are defined according to &quot;Common Terminology Criteria for Adverse Events&quot; (CTCAE), version 4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Waldenstrom's Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Bortezomib-Rituximab-Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib-Rituximab-Bendamustine</intervention_name>
    <description>Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22* Rituximab: 375 mg/sqm i.v. day 1** Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles *In case of toxicity is omitted
**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8</description>
    <arm_group_label>Bortezomib-Rituximab-Bendamustine</arm_group_label>
    <other_name>BRB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proven diagnosis of Lymphoplasmacytic/cytoid lymphoma/Waldenstrom
             macroglobulinemia according to REAL/WHO Classification

          -  Relapsed/refractory disease after receiving one line chemotherapy (rituximab). If
             patients received bortezomib or bendamustine and have obtained a partial response
             lasting at least two years.

          -  Age &gt;= 18

          -  Presence of at least one of the following criteria for the definition of active
             disease: Systemic symptoms or Hemoglobin less than 10 g/dL (due to lymphoma) or
             Platelets less than 100 x 109/L (due to lymphoma) or symptomatic splenomegaly or
             Bulky disease (&gt;7 cm) or Hyperviscosity syndrome, peripheral neuropathy up to grade 1
             (Waldenstrom's disease-related), hemolytic anemia, and immune complex vasculitis

          -  Life expectancy &gt;6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  left ventricular ejection fraction (LVEF) ≥45% or FS ≥37%

          -  Creatinine up to 1.5 x upper limit of normal

          -  Conjugated bilirubin up to 2 x upper limit of normal

          -  Alkaline phosphatase and transaminases up to 2 x upper limit of normal

          -  Written informed content

        Exclusion Criteria:

          -  Patients who received bortezomib or bendamustine first-line therapy, that or haven't
             obtained at least partial response nor partial response lasting at least two years.

          -  Patients not agreeing to take adequate contraceptive precautions during and for at
             least 6 months after cessation of therapy

          -  History of other malignancies within 3 years prior to study entry except for:
             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin
             cancer; low grade, early stage, localized prostate cancer treated surgically with
             curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated
             with lumpectomy alone with curative intent

          -  Medical condition requiring long term use (&gt;1 months) of systemic corticosteroids

          -  Active bacterial, viral, or fungal infection requiring systemic therapy

          -  Peripheral neuropathy of any grade ≥ 2 [see Appendix Section A]

          -  Concurrent medical condition which might exclude administration of therapy

          -  Cardiac insufficiency (NYHA grade III/IV)

          -  Myocardial infarction within 6 months of entry on study

          -  Severe chronic obstructive pulmonary disease with hypoxemia

          -  Severe diabetes mellitus difficult to control with adequate insulin therapy

          -  Hypertension that is difficult to control

          -  Impaired renal function with creatinine clearance &lt;30 ml/min

          -  HIV positivity HBV positivity with the exception of patients HbsAg and HBV-DNA
             negative and Ab anti-HB core positive (these patients need to receive prophylaxis
             with Lamivudine)

          -  HCV positivity with the exception of patients with HCV RNA negative

          -  Participation at the same time in another study in with investigational drugs are
             used

          -  Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

          -  Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent.

          -  Women in pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorella Orsucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC EMATOLOGIA - AO CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorella Orsucci, MD</last_name>
    <phone>011-6335610</phone>
    <email>lorsucci@cittadellasalute.to.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giulia Benevolo, MD</last_name>
    <phone>011-6335610</phone>
    <email>gbenevolo@cittadellasalute.to.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Policlinico Consorziale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AO Riuniti Papardo Piemonte</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina, MD</last_name>
      <phone>090-3992239</phone>
      <email>donamanni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico della Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>PZ</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>pellegrino.musto@crob.it</email>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi - Melacrino - Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Andriani, MD</last_name>
      <phone>+39 06 58446826</phone>
      <email>alessandro.andriani@tin.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Andriani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uo Oncoematologia, Po &quot;A.Tortora&quot;</name>
      <address>
        <city>Pagani</city>
        <state>Salerno</state>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
      <email>c.califano@aslsalerno.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giacomo di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
      <phone>+39 0131206294</phone>
      <email>segreteria@filinf.it</email>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uo Ematologia E Trapianto Emopoietico Aorn &quot;San G. Moscati&quot;</name>
      <address>
        <city>Avellino</city>
        <zip>80147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico - Oncologia Medica A</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AO Barletta</name>
      <address>
        <city>Barletta</city>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <phone>3464142695</phone>
      <email>giuseppetarantini@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annarita Conconi</last_name>
      <email>annarita.conconi@aslbi.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco, Divisione di Ematologia</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Maria Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Roberto Binaghi</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arnas Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Area Vasta Romagna e IRST</name>
      <address>
        <city>Meldola (FC)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>g.musuraca@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Martino Di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cmusolino@unime.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Musolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Policlinico Di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Baldini, MD</last_name>
      <email>luca.baldini@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Luca Baldini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Istituto Nazionale dei Tumori di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Della Carita' - Scdu Ematologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, Prof.</last_name>
      <email>gaidano@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino, Asl Oristano- Ematologia</name>
      <address>
        <city>Oristano</city>
        <zip>09170</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Casula</last_name>
      <email>paolo.casula@asloristano.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello &quot;Presidio V. Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Santo Spirito</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ausl Di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ausl Di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47924</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>annalia.molinari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita' Degli Studi Di Roma 'La Sapienza' - Roma (Rm)</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.Oo.Rr.S.Giovanni Di Dio E Ruggi D`Ar</name>
      <address>
        <city>Salerno</city>
        <zip>84100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ematologia 1 - A.O. Citta' Della Salute E Della Scienza Di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Cardinale Panico Ematologia e centro trapianti</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>francesco.passamonti@ospedale.varese.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Passamonti, Proff.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
